KR20090082401A - 안 질환 치료용 ｐａｉ－１ 결합 조절제 - Google Patents

안 질환 치료용 ｐａｉ－１ 결합 조절제 Download PDF

Info

Publication number
KR20090082401A
KR20090082401A KR1020097010021A KR20097010021A KR20090082401A KR 20090082401 A KR20090082401 A KR 20090082401A KR 1020097010021 A KR1020097010021 A KR 1020097010021A KR 20097010021 A KR20097010021 A KR 20097010021A KR 20090082401 A KR20090082401 A KR 20090082401A
Authority
KR
South Korea
Prior art keywords
pai
compound
binding
medicament
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020097010021A
Other languages
English (en)
Korean (ko)
Inventor
데브라 플리노
이억-허우 팡
애보트 클락
Original Assignee
알콘 리서치, 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알콘 리서치, 리미티드 filed Critical 알콘 리서치, 리미티드
Publication of KR20090082401A publication Critical patent/KR20090082401A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020097010021A 2006-10-31 2007-10-31 안 질환 치료용 ｐａｉ－１ 결합 조절제 Withdrawn KR20090082401A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86371506P 2006-10-31 2006-10-31
US60/863,715 2006-10-31

Publications (1)

Publication Number Publication Date
KR20090082401A true KR20090082401A (ko) 2009-07-30

Family

ID=39345074

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097010021A Withdrawn KR20090082401A (ko) 2006-10-31 2007-10-31 안 질환 치료용 ｐａｉ－１ 결합 조절제

Country Status (11)

Country Link
US (2) US20080107644A1 (enExample)
EP (1) EP2077829A2 (enExample)
JP (1) JP2010508306A (enExample)
KR (1) KR20090082401A (enExample)
CN (1) CN101588798A (enExample)
AU (1) AU2007313684A1 (enExample)
CA (1) CA2666316A1 (enExample)
MX (1) MX2009004792A (enExample)
RU (1) RU2465898C2 (enExample)
WO (1) WO2008055205A2 (enExample)
ZA (1) ZA200902453B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100158897A1 (en) * 2006-10-31 2010-06-24 Alcon Research, Ltd. Pai-1 modulators for the treatment of ocular disorders
US20090202524A1 (en) * 2007-10-31 2009-08-13 Alcon Research, Ltd. Pai-1 expression and activity inhibitors for the treatment of ocular disorders
EP2790023B1 (en) 2011-11-15 2018-07-04 National University Corporation Hamamatsu University School of Medicine Therapeutic and diagnostic agent for early delivery or abortion using plasminogen activator inhibitor-1
US10946076B2 (en) 2013-02-13 2021-03-16 The Research Foundation For The State University Of New York Glaucoma treatment
US9820954B2 (en) * 2015-08-19 2017-11-21 Jenivision Inc. Quantitative peri-orbital application of ophthalmology drugs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024121A1 (fr) * 1992-05-22 1993-12-09 Senju Pharmaceutical Co., Ltd. Medicament pour le glaucome
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
WO2000035439A1 (en) * 1998-12-11 2000-06-22 Bakulesh Mafatlal Khamar The process for manufacturing formulation of topical beta blockers with improved efficacy
CA2358400C (en) * 1999-01-05 2012-05-15 Nancy A. Noble Methods for treating conditions associated with the accumulation of excess extracellular matrix
CA2476761A1 (en) * 2002-02-19 2003-08-28 Vanderbilt University Therapeutic methods employing pai-1 inhibitors and transgenic non-human animal for screening candidate pai-1 inhibitors
KR20040104566A (ko) * 2002-04-30 2004-12-10 알콘, 인코퍼레이티드 안압 저하 및 녹내장성 망막병증/시신경병증 치료를 위한특유의 수단으로서의 결합 조직 성장 인자 (ｃｔｇｆ)의활성 및/또는 발현 조절, 저해, 또는 변조제

Also Published As

Publication number Publication date
EP2077829A2 (en) 2009-07-15
CA2666316A1 (en) 2008-05-08
ZA200902453B (en) 2010-07-28
MX2009004792A (es) 2009-05-21
WO2008055205A2 (en) 2008-05-08
CN101588798A (zh) 2009-11-25
JP2010508306A (ja) 2010-03-18
WO2008055205A3 (en) 2008-07-17
US20080107644A1 (en) 2008-05-08
AU2007313684A1 (en) 2008-05-08
US20100260784A1 (en) 2010-10-14
RU2465898C2 (ru) 2012-11-10
RU2009120545A (ru) 2010-12-10

Similar Documents

Publication Publication Date Title
CN100425241C (zh) 由Rho激酶抑制剂和前列腺素类物质构成的青光眼治疗剂
KR20090082401A (ko) 안 질환 치료용 ｐａｉ－１ 결합 조절제
US20080153903A1 (en) Inhibitors of protein kinase c-delta for the treatment of glaucoma
Lee et al. Emerging drugs for ocular hypertension
US20110105574A1 (en) Pai-1 expression and activity inhibitors for the treatment of ocular disorders
US20090098136A1 (en) Use of tnf receptor antagonists for treating dry eye
Sharif Novel potential treatment modalities for ocular hypertension: focus on angiotensin and bradykinin system axes
ES2320440T3 (es) Moleculas organicas pequeñas que aumentan la actividad de gelatinasa a en celulas oculares.
US20050233974A1 (en) Treating infectious diseases using ice inhibitors
US20100158897A1 (en) Pai-1 modulators for the treatment of ocular disorders
US20090181896A1 (en) Use of Natriuretic Peptide Receptor Antagonists to Treat Ocular, Otic and Nasal Edemetous Conditions
JP2023549762A (ja) 線維性疾患を治療するための方法および組成物
Kaplan-Messas et al. Ocular hypotensive effects of cholinergic and adrenergic drugs may be influenced by prostaglandins E2 in the human and rabbit eye
KR20080111092A (ko) 고안압증 조절 및 녹내장의 치료를 위한 프레닐트랜스퍼라아제 억제제
US20080187572A1 (en) Matrix Metalloproteinase Inhibitors of Tgfb-Induced Subcapsular Cataract Formation
US7867999B1 (en) Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions
EP1112749A2 (en) Preventives or remedies for eye circulatory failure
US6534475B1 (en) Use of TIMP-3 inducers of TIMP-3 expression, and TIMP-3 mimetics to treat ocular neovascularization
US20040086537A1 (en) Prophylactic or threapeutic composition for ocular circulation disorders
WO2001076587A1 (en) Remedies for diseases due to stenotic lesions of blood vessel
DeFaller Mechanism of action and clinical efficacy of AL-3789, an angiostatic steroid
WO2020203822A1 (ja) 血管新生を伴う網膜疾患の治療又は予防のための併用医薬
JP2000264847A (ja) 角膜障害治療剤
WO2001041781A2 (en) Id protein inhibitors for treating ocular diseases

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090515

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid